Evidence map›Paper›PMID 35409274›Full record

ArticleInternational journal of molecular sciences2022

Molecular Radiotherapy with

Tao Huang, Jae Sam Lee, Alexander L Klibanov, Jiang He

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Advanced drug delivery platforms target cancer stem cells.Asian journal of pharmaceutical sciences · 2025
    Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Tao HuangDepartment of Radiology and Medical Imaging, School of Medicine, University of Virginia, Charlottesville, VA 22903, USA.ORCID 0000-0002-6147-0490
Jae Sam LeeDepartment of Radiology and Medical Imaging, School of Medicine, University of Virginia, Charlottesville, VA 22903, USA.
Alexander L KlibanovDepartment of Medicine, Division of Cadiovascular Medicine, School of Medicine, University of Virginia, Charlottesville, VA 22903, USA.
Jiang HeDepartment of Radiology and Medical Imaging, School of Medicine, University of Virginia, Charlottesville, VA 22903, USA.
University of Virginia · US

Funding

Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Jay William FOX · 1987 to 2026
$72.1M
Targeted liposomal radiotherapy of malignant mesotheliomaR01CA135358 · NCI · UNIVERSITY OF VIRGINIA · PI HE, JIANG · 2008 to 2011
$1.0M
NCI NIH HHS P30 CA044579NCI NIH HHS R01 CA135358NCI NIH HHS R01CA135358
6 · The paper itself

Abstract

Malignant mesothelioma (MM) is a lethal tumor originating in the mesothelium with high chemotherapeutic resistance. Cancer stem cells (CSCs) persist in tumors and are critical targets responsible for tumor resistance and recurrence. The identification and characterization of CSCs may help develop effective treatment for MM. The objective of this study was to evaluate the therapeutic effect of molecular targeted radiotherapy by

Indexed as

MesotheliomaMesothelioma, MalignantCell Line, TumorDipeptidyl Peptidase 4Fluorodeoxyglucose F18HumansLiposomesNeoplastic Stem CellsDipeptidyl Peptidase 4Fluorodeoxyglucose F18Liposomes177Lucancer stem cells (CSCs)liposomesmesotheliomamolecular radiotherapyradioimmunotherapy (RIT)

Identifiers

PMID35409274
PMCPMC8999793
OpenAlexW4223645269

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.